Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin Plus MDR1 Inhibitors in R/R Hodgkin Lymphoma
NCT03013933Phase 1Completed
- Sponsor
- City of Hope
- Start
- May 2017
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brentuximab vedotin, cyclosporine and verapamil in Hodgkin lymphoma (HL), sponsored by City of Hope. Primary endpoint: Dose-limiting toxicity up to 21 days. Started May 2017; status: completed.
02
Drugs
brentuximab vedotincyclosporineverapamil
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT03013933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03013933.